On August 28, 2018 Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) reported that Adelene Perkins, Infinity Pharmaceuticals’ Chief Executive Officer, and Lawrence Bloch, Infinity Pharmaceuticals’ President, will present at the following conferences (Press release, Infinity Pharmaceuticals, AUG 28, 2018, View Source [SID1234529119]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 20th Annual Global Investment Conferencein New York, NY on Wednesday September 5, 2018 at 1:45 p.m. ET

Wells Fargo Securities 2018 Healthcare Conference in Boston, MA on Thursday, September 6, 2018 at 1:55 p.m. ET

25th Annual BioCentury NewsMakers in the Biotech Industry in New York, NY on Friday, September 7, 2018 at 8:30 a.m. ET. Additionally, for those who will be attending BioCentury NewsMakers, Adelene Perkins will be participating in the lunch panel from 12:15 – 1:15 p.m. ET on "Investing In Hot Topics Areas" moderated by Simone Fishburn, BioCentury’s VP and Executive Editor.

A live webcast of the presentation for each of these conferences, excluding the BioCentury NewsMakers lunch panel discussion, will be available on the Investors/Media section of Infinity’s website at www.infi.com, and will be available for 30 days following the event.

On August 28, 2018 AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, reported that it will participate in the Morgan Stanley 16th Annual Global Healthcare Conference on Wednesday, September 12, 2018 (Press release, AbbVie, AUG 28, 2018, View Source [SID1234529099]). Bill Chase, executive vice president and chief financial officer, will present at 10:40 a.m. Central time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation will be accessible through AbbVie’s Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.

On August 28, 2018 INmune Bio Inc., an immunotherapy company developing treatments to reprogram the innate immune system to fight disease, reported that its co-founder and CEO, Raymond J. Tesi, M.D., will participate in a panel at the Immuno-Oncology Investing & Partnering Forum on Aug. 30. He will also chair a session and present at the 2nd Annual Emerging Immuno-Oncology Targets Conference on August 31 (Press release, INmune Bio, AUG 28, 2018, View Source [SID1234529238]). Both conferences will take place in Boston.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"It is a privilege to present to many of the leading minds in immunotherapy from both academia and industry," said Dr. Tesi. "Understanding why some patients are resistant to immunotherapy is vital as immunotherapy becomes the backbone of cancer treatment. We believe reprogramming the innate system to allow for more effective immunotherapy is key to solving this problem."

During Dr. Tesi’s panel at the Immuno-Oncology Investing & Partnering Forum, titled "Novel Therapeutics in Cancer Immunotherapy," he will discuss new immunotherapy drugs and therapeutic strategies in an attempt to highlight new approaches in the field.

The inaugural Immuno-Oncology Investing & Partnering Forum will be hosted by Cambridge Healthtech Institute as part of the Immuno-Oncology Summit. The forum brings together early and late-stage investors, fundraising CEOs and research entrepreneurs to encourage partnering and investment and to boost the immunotherapy market.

At the Emerging Immuno-Oncology Targets Conference, Dr. Tesi will present "Targeting Soluble TNF in Tumor Microenvironment (TME) to Reverse Resistance to Immunotherapy." His talk will highlight the role of chronic inflammation as a cause for failed checkpoint inhibitor therapies and will discuss how neutralizing soluble tumor necrosis factor (TNF) in the TME can target MDSC, a major cause of resistance to checkpoint inhibitors and other immunotherapies.

The Emerging Immuno-Oncology Targets conference, also hosted by Cambridge Healthtech Institute, covers the emerging target space, including immunomodulatory inhibitor and agonist targets, stromal and immune cell targets, and strategies for rational combination immunotherapy.

Details of the presentations are as follows:
Immuno-Oncology Investing & Partnering Forum
Session Title: Novel Therapeutics in Cancer Immunotherapy
Date and Time: August 30, 2018, at 1:30 p.m.
Location: Seaport World Trade Center, Boston, Massachusetts

Emerging Immuno-Oncology Targets
Title: Emerging Cytokine Targets
Session Title: Targeting Soluble TNF in Tumor Microenvironment (TME) to Reverse Resistance to Immunotherapy
Date and Time: August 31, 2018, at 9:05 a.m.
Location: Seaport World Trade Center, Boston, Massachusetts

On August 28, 2018 Novavax, Inc. (NASDAQ: NVAX) reported that Novavax will participate in the B. Riley FBR Annual Healthcare Conference and the Citi 13th Annual Biotech Conference in September (Press release, Novavax, AUG 28, 2018, View Source [SID1234529100]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference details are as follows:

B. Riley FBR Annual Healthcare Conference

Title: "Vaccine & Antibiotics Can’t Be Developed For Some Intractable Infectious Diseases"
Date and Time: Tuesday, September 4, 1:55 – 2:55 p.m.
Moderator: George Zavoico, B. Riley FBR
Panelists: Vivek Shinde, M.D., M.P.H., Executive Director of Clinical Development, Novavax
Robert Stein, M.D., Ph.D., Senior R&D Advisor, Agenus
Location: New York Marriott East Side

Citi 13th Annual Biotech Conference

Date: Thursday, September 6
Forum: Investor meetings
Location: Four Seasons Hotel Boston

On August 28, 2018 Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, reported that the Company will present at the Baird 2018 Global Healthcare Conference on Wednesday, September 5 at 2:35-3:05 PM in Session III – Empire Ballroom B, Mezzanine Level of the InterContinental New York Barclay in New York (Press release, Curis, AUG 28, 2018, View Source [SID1234529101]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be held using a fireside-chat format in which Ali Fattaey, Ph.D. President and Chief Executive Officer, will provide a brief overview of the Company’s pipeline of drug candidates and business strategy, after which an equity analyst will moderate a question and answer session.

A live webcast of the presentation will be available by visiting the investors section of Curis’ website View Source

A replay of the webcast will be archived on the website for 30 days following the presentation.